<DOC>
	<DOC>NCT00107016</DOC>
	<brief_summary>The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.</brief_summary>
	<brief_title>Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologicallyconfirmed diagnosis of invasive breast cancer, previously untreated Patients must be postmenopausal Candidates for mastectomy or breastconserving surgery Primary tumor of above 2 cm diameter, measured by imaging Clinical Stage M0 WHO performance status â‰¤1 Adequate bone marrow, liver, and renal function Multicentric invasive tumors Bilateral or inflammatory breast cancer Receiving concomitant anticancer treatments such as chemotherapy Patients with an uncontrolled infection Patients with other concurrent severe and/or uncontrolled medical disease Additional protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer of the Breast</keyword>
	<keyword>Neo-adjuvant</keyword>
	<keyword>Primary breast cancer</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>pre-operative</keyword>
</DOC>